IHTC NEWS:
09.11.2010 - Sickle Cell-abration 2010
The IHTC is sponsoring a free concert to raise awareness of sickle cell disease! Come and enjoy a diverse blend of music at the Madame Walker Theater. The free concert is from 5 to 9 pm; doors open at 4:30 pm. You may also choose to share the gift of life with those who have sickle cell disease by...
04.20.2010 - IHTC voted one of Indiana's best workplaces!
As reported in the IndyStar, over 600 companies in central Indiana were invited by Workplace Dynamics of Exton, PA, to participate in a workplace survey in January 2010. Nearly 20,000 employees from 101 large, middle, and small companies voted on their workplace management,...
Benefits to Payors
Benefits to Payors
HMO Plan: "We want to work with the IHTC Pharmacy Program because we know their clotting factor prices are lower than our preferred arrangement." National Reinsurance Carrier: "We try to use the IHTC for our hemophilia members. The IHTC provides quality care and their clotting factor prices are the lowest we have seen." National Case Management Company: "We want to work with the IHTC because their clotting factor prices are the most competitive we have seen."
The IHTC is Indiana’s only federally recognized hemophilia treatment center and is a center of excellence for the treatment of individuals with bleeding or thrombotic disorders. The IHTC provides:
- Free annual comprehensive clinic evaluations with our multidisciplinary team – a service that saves payors in excess of $170,000 annually
- Integrated care management and coordination with healthcare providers and payors
- Telephone triage, with 24/7 physician and pharmacist availability for clinical and pharmacy needs
- Significantly discounted clotting factor pricing available through the Public Health Service 340B program – a service that saves payors in excess of $12,000,000 annually
- A bleeding disorder disease management program (DMP) with documented, sustained results that have lead to reductions in emergency room visits, inpatient hospital days, outpatient medical costs, clotting factor utilization and costs while maintaining quality care and quality of life
- Clinical research studies with provision of new therapies that may provide free clotting factor concentrate to eligible participants – a service that saves payors in excess of $500,000 annually.
